

**Minutes of the June 5, 2015  
Pharmacy & Therapeutics (P&T) Committee Meeting  
South Dakota Department of Social Services, Division of Medical Services**

**Members present**

Bill Ladwig, RPh; M. Holland; R. Holm; Lenny Petrik; Deb Farver; Kelley Oehlke; J. Engelbrecht

**DSS staff present**

Mike Jockheck, RPh; Ann Schwartz, Dep. Director of Medical Services.

**Administrative business**

The P&T meeting was called to order by D. Farver at 1:00 p.m. The minutes of the March 20, 2015 meeting were presented. R. Holm made a motion to approve. K. Oehlke seconded the motion. The motion was approved unanimously.

**Prior authorization update and statistics**

The committee reviewed the prior authorization (PA) activity for April 2015. There were a total of 3,315 PAs processed in the month of April, with 99.91% of those requests responded to in less than eight hours. There were 2,582 requests (78%) received electronically and 733 requests (22%) received by fax.

**Analysis of the top 15 therapeutic classes**

The committee reviewed the top 15 therapeutic classes by total cost of claims from 01/1/2015 – 03/31/2015. The top five classes were antipsychotics, respiratory and CNS stimulants, central nervous system agents, misc., amphetamines, and insulins. The top 15 therapeutic classes make up 41.02% of total claims. The committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 13.52% of total claims. The committee requested that the top 25 drug list be expanded to the top 50 drugs for future meetings.

**Review of drug spend**

The committee reviewed a table showing SD Medicaid drug spend from 2012 – 2014. The average cost per script rose from \$64.45 in 2012 to \$77.87 in 2014. The average recipient script cost rose from \$172.76 in 2012 to \$212.12 in 2014.

**Patent Expirations**

The committee reviewed a list of medications with an upcoming anticipated availability of a first-time generic.

**Agents used to treat idiopathic pulmonary fibrosis review**

The committee reviewed the prior authorization form provided for agents used to treat idiopathic pulmonary fibrosis (IPF). J. Crumwell, representing Boehringer Ingelheim, spoke regarding Ofev. B. Ladwig made a motion to remove FVC and approve the IPF form. R. Holm seconded the motion. The motion was approved unanimously.

**Xtoro review**

The committee reviewed the prior authorization form provided for Xtoro. There was no public comment. M. Holland made a motion to approve the Xtoro form. B. Ladwig seconded the motion. The motion was approved unanimously.

**Hemangeol review**

The committee reviewed the prior authorization form provided for Hemangeol. There was no public comment. J. Engelbrecht made a motion to approve the Hemangeol form. R. Holm seconded the motion. The motion was approved unanimously.

**Trokendi review**

The committee reviewed Trokendi clinical information. There was no public comment. The committee tabled this topic.

**Oxtellar XR review**

The committee reviewed Oxtellar XR clinical information. There was no public comment. The committee tabled this topic.

**Akynzeo review**

The committee reviewed Akynzeo clinical information. There was no public comment. The committee requested that a form be developed and brought back to the September meeting.

**Nuessa review**

The committee reviewed Nuessa clinical information. There was no public comment. The committee requested that a form be developed and brought back to the September meeting.

**Cholbam review**

The committee reviewed Cholbam clinical information. There was no public comment. The committee tabled this topic.

**Copaxone 40 review**

The committee reviewed Copaxone 40 clinical information. There was no public comment. The committee tabled this topic.

The next meeting is scheduled for September 4, 2015. R. Holm made a motion to adjourn the P&T Committee meeting. B. Ladwig seconded the motion. The motion passed unanimously and the meeting was adjourned.